547 related articles for article (PubMed ID: 28514486)
21. Newer atypical antipsychotic medication versus clozapine for schizophrenia.
Tuunainen A; Wahlbeck K; Gilbody SM
Cochrane Database Syst Rev; 2000; (2):CD000966. PubMed ID: 10796559
[TBL] [Abstract][Full Text] [Related]
22. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.
Nitta M; Kishimoto T; Müller N; Weiser M; Davidson M; Kane JM; Correll CU
Schizophr Bull; 2013 Nov; 39(6):1230-41. PubMed ID: 23720576
[TBL] [Abstract][Full Text] [Related]
23. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Smith RC; Leucht S; Davis JM
Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
[TBL] [Abstract][Full Text] [Related]
24. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
25. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials.
Zheng W; Xiang YT; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Correll CU
Acta Psychiatr Scand; 2016 Nov; 134(5):385-398. PubMed ID: 27585549
[TBL] [Abstract][Full Text] [Related]
27. Risperidone versus other atypical antipsychotic medication for schizophrenia.
Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
[TBL] [Abstract][Full Text] [Related]
28. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.
Sommer IE; Begemann MJ; Temmerman A; Leucht S
Schizophr Bull; 2012 Sep; 38(5):1003-11. PubMed ID: 21422107
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
Singh SP; Singh V
CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
[TBL] [Abstract][Full Text] [Related]
31. Augmentation of clozapine with a second antipsychotic - a meta-analysis.
Taylor DM; Smith L; Gee SH; Nielsen J
Acta Psychiatr Scand; 2012 Jan; 125(1):15-24. PubMed ID: 22077319
[TBL] [Abstract][Full Text] [Related]
32. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
33. Benzodiazepines for schizophrenia.
Volz A; Khorsand V; Gillies D; Leucht S
Cochrane Database Syst Rev; 2007 Jan; (1):CD006391. PubMed ID: 17253592
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.
Galling B; Roldán A; Rietschel L; Hagi K; Walyzada F; Zheng W; Cao XL; Xiang YT; Kane JM; Correll CU
Expert Opin Drug Saf; 2016 May; 15(5):591-612. PubMed ID: 26967126
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis.
Tiihonen J; Wahlbeck K; Kiviniemi V
Schizophr Res; 2009 Apr; 109(1-3):10-4. PubMed ID: 19186030
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials.
Siafis S; Schneider-Thoma J; Hamza T; Bighelli I; Dong S; Hansen WP; Davis JM; Salanti G; Leucht S
BMJ Open; 2023 Feb; 13(2):e064504. PubMed ID: 36810167
[TBL] [Abstract][Full Text] [Related]
37. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.
Sommer IE; de Witte L; Begemann M; Kahn RS
J Clin Psychiatry; 2012 Apr; 73(4):414-9. PubMed ID: 22225599
[TBL] [Abstract][Full Text] [Related]
38. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.
Matsui K; Tokumasu T; Takekita Y; Inada K; Kanazawa T; Kishimoto T; Takasu S; Tani H; Tarutani S; Hashimoto N; Yamada H; Yamanouchi Y; Takeuchi H
Schizophr Res; 2019 Jul; 209():50-57. PubMed ID: 31182319
[TBL] [Abstract][Full Text] [Related]
39. Does the addition of a second antipsychotic drug improve clozapine treatment?
Barbui C; Signoretti A; Mulè S; Boso M; Cipriani A
Schizophr Bull; 2009 Mar; 35(2):458-68. PubMed ID: 18436527
[TBL] [Abstract][Full Text] [Related]
40. Antipsychotic combinations in schizophrenia.
Gastaldon C; Papola D; Ostuzzi G
Epidemiol Psychiatr Sci; 2017 Oct; 26(5):462-465. PubMed ID: 28578741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
